Klivira
Request demo

Streamlining Ultomiris Prior Authorization for Oncology

Navigating the complexities of Ultomiris prior authorization for oncology patients is a significant operational challenge for revenue cycle and prior authorization teams. Klivira's automation platform is purpose-built to accelerate this critical process.

Oncology care, particularly for high-cost biologics like Ultomiris, demands a high volume of prior authorizations across commercial, Medicare Advantage, and Medicaid managed care plans. The unique cadence of cancer treatment—from initial diagnosis and staging through multiple lines of therapy and supportive care—necessitates a robust and efficient PA workflow to prevent treatment delays and reduce administrative burden.

The PA Landscape for Oncology Biologics

Biologics and immuno-oncology agents, including J-code infusions like Ultomiris, represent a major category for prior authorization in cancer care. Each treatment cycle, regimen change, or even supportive care medication can trigger a new PA event. This high-frequency requirement, coupled with the clinical urgency inherent in oncology, makes efficient processing of PA for agents like Ultomiris paramount.

Key Documentation for Ultomiris PA in Oncology

  • **Diagnosis Confirmation:** Pathology reports, tumor staging (AJCC TNM), and molecular markers (e.g., EGFR, ALK, PD-L1, BRCA, MSI/MMR) relevant to the proposed treatment.
  • **Treatment Rationale:** For subsequent lines of therapy, documentation of prior regimens, response duration, and clear rationale for the proposed Ultomiris regimen (e.g., progression, toxicity).
  • **Performance Status:** ECOG or Karnofsky score to support the patient's fitness for treatment.
  • **Comorbidities and Contraindications:** Assessment of organ function and prior toxicities relevant to the proposed therapy.
  • **NCCN Guideline Adherence:** Citation from the NCCN Clinical Practice Guidelines or NCCN Drugs & Biologics Compendium for on-label or compendium-supported off-label use.

Navigating Medical vs. Pharmacy Benefit for Oncology Biologics

For provider-administered infusions like Ultomiris, prior authorization typically routes through the medical benefit. This involves payer-specific portals or EDI transactions via X12 278. This contrasts with oral oncology drugs, which usually fall under the pharmacy benefit and are processed through PBMs and ePA partners. Klivira's platform is designed to intelligently route PA requests based on the specific drug and benefit type, ensuring the correct pathway is followed for Ultomiris and other oncology agents.

Common Denial Factors for Biologics like Ultomiris in Oncology

  • **Off-Label Use Without Compendium Support:** Requests for indications not supported by recognized compendia like the NCCN Compendium (src: nccn-compendium).
  • **Step Therapy Requirements:** Payer mandates for failure or contraindication to a less costly alternative, common for biologics with biosimilar options.
  • **Documentation Gaps:** Missing pathology details, incomplete prior-line treatment history, or unsubmitted molecular marker results.
  • **NCD/LCD Non-Coverage:** For Medicare Advantage plans, denials based on Original Medicare's National or Local Coverage Determinations (src: cms-ncds).
  • **Site-of-Service Mismatch:** Discrepancies between the requested infusion site (e.g., HOPD vs. freestanding infusion center) and payer policy.

Klivira's Solution for Ultomiris Prior Authorization in Oncology

Klivira's prior authorization automation platform addresses the unique challenges of oncology PA for biologics like Ultomiris. Our system incorporates NCCN-compendium-aware policy logic to guide documentation, supports regimen-level PA workflows, and manages the medical-vs-pharmacy benefit split. We provide concurrent PA tracking for the multiple events per patient and integrate with peer-to-peer scheduling to expedite clinical-necessity denials, reducing delays in critical cancer care.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for Ultomiris?

Klivira's platform intelligently identifies whether Ultomiris, as an IV biologic, falls under the medical benefit and routes the prior authorization request accordingly. This ensures submissions are directed to the correct payer channel, whether via X12 278 EDI or specific payer portals, bypassing common misrouting errors.

What role do NCCN guidelines play in Ultomiris oncology PAs processed by Klivira?

Klivira integrates NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium into its policy logic. For Ultomiris, the system automatically prompts for required documentation based on the specific tumor type and proposed line of therapy, ensuring submissions align with widely accepted medical necessity criteria (src: nccn-guidelines, nccn-compendium).

How does Klivira address common denial reasons for oncology biologics like Ultomiris?

Klivira proactively identifies potential denial risks, such as documentation gaps or non-adherence to step therapy protocols, before submission. For denials related to clinical necessity, our platform facilitates efficient peer-to-peer review scheduling, connecting oncologists directly with payer medical directors to appeal and overturn denials.

Can Klivira integrate with our EMR for Ultomiris PA submissions?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to pull relevant patient data directly from your EMR. This reduces manual data entry for Ultomiris prior authorizations, ensuring accuracy and saving significant staff time for your oncology practice.

How does Klivira support the high volume of PAs for oncology patients receiving Ultomiris?

Oncology patients often require dozens of PA events over their treatment course. Klivira's platform provides concurrent PA tracking across all services—including regimen changes, supportive care, and imaging—for each patient. This comprehensive oversight helps manage the high volume efficiently and reduces the risk of lapsed authorizations.

Related coverage

Other ultomiris prior authorization by payer

Other ultomiris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo